These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 33221367)

  • 21. Sero-surveillance for SARS-CoV-2 infection among healthcare providers in four hospitals in Thailand one year after the first community outbreak.
    Kittikraisak W; Piyaraj P; Vachiraphan A; Wongrapee T; Punjasamanvong S; Hunsawong T; Sinthuwattanawibool C; Leepiyasakulchai C; Yoocharoen P; Azziz-Baumgartner E; Mott JA; Chottanapund S
    PLoS One; 2021; 16(7):e0254563. PubMed ID: 34260638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020.
    Yoshiyama T; Saito Y; Masuda K; Nakanishi Y; Kido Y; Uchimura K; Mitarai S; Suzuki T; Nakagama Y; Kubota H; Satomi M; Uchikoba S; Ohnishi M; Wakita T; Kato S; Kato K
    Emerg Infect Dis; 2021 Feb; 27(2):628-631. PubMed ID: 33496235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam.
    Mai HK; Trieu NB; Long TH; Thanh HT; Luong ND; Huy LX; Nguyet LA; Man DNH; Anderson DE; Thanh TT; Chau NVV; Thwaites G; Wang LF; Van Tan L; Hung DT
    Emerg Infect Dis; 2021 Feb; 27(2):663-666. PubMed ID: 33496647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sero-Prevalence of SARS-CoV-2 Antibodies in High-Risk Populations in Vietnam.
    Hasan T; Pham TN; Nguyen TA; Le HTT; Van Le D; Dang TT; Van TD; Pham YN; Nguyen HV; Tran GL; Nguyen VTC; Nguyen TT; Truong VQ; Dao TH; Le CT; Truong NT; Vo HT; Le PT; Nguyen TT; Van Luu V; Nguyen VD; Toelle BG; Marks GB; Fox GJ
    Int J Environ Res Public Health; 2021 Jun; 18(12):. PubMed ID: 34208212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seroprevalence of SARS-CoV-2 IgG specific antibodies among healthcare workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave.
    Barallat J; Fernández-Rivas G; Quirant-Sánchez B; González V; Doladé M; Martinez-Caceres E; Piña M; Matllo J; Estrada O; Blanco I
    PLoS One; 2020; 15(12):e0244348. PubMed ID: 33370363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS Trust.
    Grant JJ; Wilmore SMS; McCann NS; Donnelly O; Lai RWL; Kinsella MJ; Rochford HL; Patel T; Kelsey MC; Andrews JA
    Infect Control Hosp Epidemiol; 2021 Feb; 42(2):212-214. PubMed ID: 32746953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective Sero-epidemiological Evaluation of SARS-CoV-2 among Health Care Workers in a German Secondary Care Hospital.
    Herzberg J; Vollmer T; Fischer B; Becher H; Becker AK; Sahly H; Honarpisheh H; Guraya SY; Strate T; Knabbe C
    Int J Infect Dis; 2021 Jan; 102():136-143. PubMed ID: 33075538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.
    Flehmig B; Schindler M; Ruetalo N; Businger R; Bayer M; Haage A; Kirchner T; Klingel K; Normann A; Pridzun L; Tougianidou D; Ranke MB
    Viruses; 2020 Nov; 12(12):. PubMed ID: 33260809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence, Persistence, and Factors Associated with SARS-CoV-2 IgG Seropositivity in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital in Northern Italy.
    Scozzari G; Costa C; Migliore E; Coggiola M; Ciccone G; Savio L; Scarmozzino A; Pira E; Cassoni P; Galassi C; Cavallo R; The Collaborative Group
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34205134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 IgG seroprevalence among medical staff in a general hospital that treated patients with COVID-19 in Japan: retrospective evaluation of nosocomial infection control.
    Hibino M; Iwabuchi S; Munakata H
    J Hosp Infect; 2021 Jan; 107():103-104. PubMed ID: 33039454
    [No Abstract]   [Full Text] [Related]  

  • 31. Induction of Humoral and Cellular Immunity by Intradermal Delivery of SARS-CoV-2 Nucleocapsid Protein Using Dissolvable Microneedles.
    Kuwentrai C; Yu J; Zhang BZ; Hu YF; Dou Y; Gong HR; Huang JD; Xu C
    J Immunol Res; 2021; 2021():5531220. PubMed ID: 34056008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 antibodies in healthcare workers in a large university hospital, Kerala, India.
    Kumar A; Sathyapalan D; Ramachandran A; Subhash K; Biswas L; Beena KV
    Clin Microbiol Infect; 2021 Mar; 27(3):481-483. PubMed ID: 32949718
    [No Abstract]   [Full Text] [Related]  

  • 33. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence.
    Hartley GE; Edwards ESJ; Aui PM; Varese N; Stojanovic S; McMahon J; Peleg AY; Boo I; Drummer HE; Hogarth PM; O'Hehir RE; van Zelm MC
    Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33443036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The seroprevalence of SARS-CoV-2 in a rural southwest community.
    Santarelli A; Lalitsasivimol D; Bartholomew N; Reid S; Reid J; Lyon C; Wells J; Ashurst J
    J Osteopath Med; 2021 Feb; 121(2):199-210. PubMed ID: 33567087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
    Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
    Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals.
    Alserehi HA; Alqunaibet AM; Al-Tawfiq JA; Alharbi NK; Alshukairi AN; Alanazi KH; Bin Saleh GM; Alshehri AM; Almasoud A; Hashem AM; Alruwaily AR; Alaswad RH; Al-Mutlaq HM; Almudaiheem AA; Othman FM; Aldakeel SA; Abu Ghararah MR; Jokhdar HA; Algwizani AR; Almudarra SS; Albarrag AM
    Diagn Microbiol Infect Dis; 2021 Mar; 99(3):115273. PubMed ID: 33296851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
    Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
    Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
    Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
    PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review.
    Lai CC; Wang JH; Hsueh PR
    Int J Infect Dis; 2020 Dec; 101():314-322. PubMed ID: 33045429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seroprevalence of SARS-CoV-2 IgG antibodies in the current COVID-19 pandemic amongst co-workers at a UK renal transplant centre.
    Black JT; Haroon U; Barnes SC; Mayaleh S; Bagul A
    Transpl Int; 2021 Feb; 34(2):382-383. PubMed ID: 33320975
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.